Sonnet BioTherapeutics Holdings Management

Management Kriterienprüfungen 2/4

Sonnet BioTherapeutics Holdings' CEO ist Pankaj Mohan , ernannt in Jan 2015, hat eine Amtszeit von 9.42 Jahren. Die jährliche Gesamtvergütung beträgt $1.02M , bestehend aus 52.7% Gehalt und 47.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 2.01% der Aktien des Unternehmens, im Wert von $98.94K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.1 Jahre bzw. 4.7 Jahre.

Wichtige Informationen

Pankaj Mohan

Geschäftsführender

US$1.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	52.7%
Amtszeit als Geschäftsführer	9.7yrs
Eigentum des Geschäftsführers	1.2%
Durchschnittliche Amtszeit des Managements	5.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.9yrs

Jüngste Management Updates

Recent updates

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Oct 04

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sep 16

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Jul 22

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Dec 19

Sonnet Bio issued U.S. patent for its albumin binding technology

Jun 08

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

May 03

Sonnet BioTherapeutics reports FY results

Dec 17

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Pankaj Mohan im Vergleich zu den Einnahmen von Sonnet BioTherapeutics Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	US$1m	US$539k	-US$19m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	n/a	n/a	-US$29m
Sep 30 2022	US$1m	US$560k	-US$30m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	n/a	n/a	-US$25m
Sep 30 2021	US$792k	US$512k	-US$25m
Jun 30 2021	n/a	n/a	-US$67m
Mar 31 2021	n/a	n/a	-US$73m
Dec 31 2020	n/a	n/a	-US$69m
Sep 30 2020	US$2m	US$490k	-US$66m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$7m
Sep 30 2019	US$548k	US$368k	-US$5m

Vergütung im Vergleich zum Markt: PankajDie Gesamtvergütung ($USD1.02M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: PankajDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Pankaj Mohan (59 yo)

9.7yrs

Amtszeit

US$1,022,720

Vergütung

Dr. Pankaj Mohan, Ph.D. founded Sonnet BioTherapeutics Holdings, Inc. in 2015 and has since served as a member of its Board of Directors. Dr. Mohan has been Chairman of Sonnet BioTherapeutics Holdings, Inc...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pankaj Mohan	Founder	9.7yrs	US$1.02m	1.2% $ 44.4k
John Cini	Chief Scientific Officer & Co-Founder	9.7yrs	US$626.41k	0.035% $ 1.3k
Jay Cross	Chief Financial Officer	5.3yrs	US$619.25k	0.021% $ 771.2
Donald Griffith	Controller & Director	5.7yrs	US$137.33k	0.0062% $ 228.5
Susan Dexter	Chief Technical Officer	4.4yrs	keine Daten	0.029% $ 1.1k
Richard Kenney	Chief Medical Officer	3.4yrs	keine Daten	0.015% $ 558.6
Manuel Dafonseca	Head of Clinical Operations	3.5yrs	keine Daten	keine Daten

5.3yrs

Durchschnittliche Betriebszugehörigkeit

67.5yo

Durchschnittliches Alter

Erfahrenes Management: SONNDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.1 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Pankaj Mohan	Founder	9.7yrs	US$1.02m	1.2% $ 44.4k
Donald Griffith	Controller & Director	9.4yrs	US$137.33k	0.0062% $ 228.5
Hossein Borghaei	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Lori McNeill	Independent Director	2yrs	US$73.85k	0% $ 0
Albert Dyrness	Independent Director	4.9yrs	US$59.35k	0.022% $ 812.5
Nailesh Bhatt	Independent Director	6.2yrs	US$57.85k	0.024% $ 869.4
Guido Cavaletti	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Raghu Rao	Independent Director	4.8yrs	US$120.35k	0.30% $ 11.1k
Jason Bock	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Robert Wenham	Member of Scientific Advisory Board	2yrs	keine Daten	keine Daten

4.9yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: SONNDie Vorstandsmitglieder gelten als erfahren (4.7 Jahre durchschnittliche Amtszeit).

Sonnet BioTherapeutics Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Founder recently bought US$83k worth of stock

Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022

High number of new directors

Recent updates

Sonnet BioTherapeutics Holdings, Inc Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Nasdaq Hearings Panel Grants Sonnet BioTherapeutics Holdings, Inc. an Exception Until October 15, 2024 to Regain Compliance with the $1.00 Minimum Bid Price Requirement

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Consensus EPS estimates upgraded to US$1.95 loss

Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting

Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target

Consensus revenue estimates increase by 42%, EPS downgraded

Second quarter 2024 earnings released: EPS: US$0.079 (vs US$7.55 loss in 2Q 2023)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$1.82 loss in 3Q 2022)

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab

Founder recently bought US$83k worth of stock

Price target decreased by 13% to US$10.35

Consensus revenue estimates decrease by 50%, EPS upgraded

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $14.999777 million.

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010

Price target decreased to US$25.00

Sonnet BioTherapeutics Holdings, Inc. Announces Interim Data in Two Phase 1 Dose-Escalation Trials of Son-1010

Nasdaq Listing Qualifications Staff Grants an Extension to Sonnet

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sonnet BioTherapeutics Holdings Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.25 million in funding

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Price target decreased to US$2.25

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022

Nasdaq Grants Extension to Sonnet BioTherapeutics Holdings Till October 03, 2022 to Regain Compliance

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Sonnet BioTherapeutics Holdings, Inc. Selects Novel Development Candidate After Completing Comparative Studies in a Mouse Melanoma Model

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

High number of new directors

Sonnet Bio issued U.S. patent for its albumin binding technology

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

New 90-day low: US$2.07

New 90-day high: US$3.10

Sonnet BioTherapeutics reports FY results

New 90-day high: US$2.98

New 90-day low: US$2.42

New 90-day low - US$2.46

New 90-day low - US$2.63

SONNET BioTherapeutics, Inc. completed the acquisition of Chanticleer Holdings, Inc. (NasdaqCM:BURG) in a reverse merger transaction.

Sonnet BioTherapeutics Holdings, Inc. completed the acquisition of Relief Therapeutics SA from Relief Therapeutics Holding AG (SWX:RLF).

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter